The Tissue Type Plasminogen Activator pipeline drugs market research report outlays comprehensive information on the Tissue Type Plasminogen Activator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tissue Type Plasminogen Activator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Infectious Disease, and Respiratory which include the indications Acute Ischemic Stroke, Myocardial Infarction, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Bronchitis, and Acute Respiratory Failure. It also reviews key players involved in Tissue Type Plasminogen Activator targeted therapeutics development with respective active and dormant or discontinued products.
The Tissue Type Plasminogen Activator pipeline targets constitutes close to ten molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, and Discovery stages are 1, 4, 1, and 1 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 1, and 1 molecule.
Tissue Type Plasminogen Activator overview
Tissue-type plasminogen activator (tPA) is a serine protease that plays a key role in the fibrinolysis pathway, which is the process of breaking down blood clots. It is produced in endothelial cells and has important functions in regulating the blood clotting system. tPA is primarily produced by endothelial cells lining blood vessels. It is released into the bloodstream as an inactive precursor called plasminogen activator.
For a complete picture of Tissue Type Plasminogen Activator’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
